| General Information |
| Business: |
Note: Aurion Biotech withdrew its plans for an IPO in a letter to the SEC dated May 23, 2025. Alcon, Aurion’s largest shareholder, bought a majority stake in Aurion Biotech in March 2025.
We are a commercial-stage biotech focused on developing regenerative cell therapies for eye diseases. We are working on advancing a single allogeneic cell therapy to treat vision loss due to corneal endothelial diseases.
Our first-generation cell therapy product obtained regulatory approval in Japan – and subsequently it received reimbursement approval. We launched that product commercially in September 2024 and marketed it as Vyznova.
AURN001, our next-generation candidate, is an improved formula designed to be identical to Vyznova and to offer enhanced benefits. We have enrolled and dosed 97 people in a Phase 1/2 trial for AURN001 in the U.S. and Canada. We expect 12-month data from this trial in the second half of 2025.
Note: Net loss and revenue are for the 12 months that ended Sept. 30, 2024.
|
| Industry: |
Pharmaceuticals |
| Employees: |
|
| Founded: |
2016 |
| Contact Information |
| Address |
Seattle |
| Phone Number |
|
| Web Address |
|
| View Prospectus: |
Aurion Biotech |
| Financial Information |
| Market Cap |
|
| Revenues |
$0.66 mil (last 12 months) |
| Net Income |
$-59.92 mil (last 12 months) |
| IPO Profile |
| Symbol |
AURN |
| Exchange |
NYSE |
| Shares (millions): |
0.0 |
| Price range |
$0.00 - $0.00 |
| Est. $ Volume |
$100.0 mil |
| Manager / Joint Managers |
J.P.Morgan/BofA Securities/Piper Sandler/Wells Fargo Securities |
| CO-Managers |
|
| Expected To Trade: |
|
|
Status:
|
Withdrawn |
| Quiet Period Expiration Date: |
Available only to Subscribers |
| Lock-Up Period Expiration Date: |
Available only to Subscribers |
| SCOOP Rating |
Available only to Subscribers |
| Rating Change |
Available only to Subscribers |
